Pfizer (PFE) Revenue — Quarter Ended Sep 28, 2025
Revenue increased sequentially but declined compared to the same period last year. The company's top line showed improvement from the prior quarter, yet remained below the year-ago level.
Key takeaway
Quarter ended Sep 28, 2025 · FY2025 Q3
Revenue increased sequentially but declined compared to the same period last year. The company's top line showed improvement from the prior quarter, yet remained below the year-ago level.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$16.7B
Revenue reported for this quarter.
Quarter-over-quarter
+13.7%
Change from the immediately preceding quarter.
Year-over-year
-5.9%
Change from the comparable year-ago quarter.
Trailing four quarters
$62.8B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2024 | $17.8B | +21.9% |
| Mar 30, 2025 | $13.7B | -7.8% |
| Jun 29, 2025 | $14.7B | +10.3% |
| Sep 28, 2025 | $16.7B | -5.9% |
Revenue performance
The quarter benefited from recent business development activities and a voluntary pricing agreement with the U.S. government aimed at making certain drug prices more comparable internationally.
Quarterly comparison
Compared to the immediately preceding quarter, revenue rose, reflecting stronger sequential momentum. However, versus the same quarter one year earlier, revenue contracted, indicating a year-over-year headwind.
What to watch
The implementation of the government pricing agreement and its impact on future revenue trends warrants close monitoring.